These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8971471)

  • 41. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antisense comes of age.
    Flanagan WM
    Cancer Metastasis Rev; 1998 Jun; 17(2):169-76. PubMed ID: 9770113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of protein kinase C-alpha in hematologic malignancies.
    Lahn M; Sundell K; Köhler G
    Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
    Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
    Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance.
    Javanmardi S; Aghamaali MR; Abolmaali SS; Mohammadi S; Tamaddon AM
    Curr Gene Ther; 2017; 16(6):375-389. PubMed ID: 28042781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense therapeutics in oncology: points to consider in their clinical evaluation.
    Mani S; Gu Y; Wadler S; Fingert H
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):543-7. PubMed ID: 10645781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense strategies in the treatment of leukemias.
    Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
    Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense therapeutics: a promise waiting to be fulfilled.
    Phillips MI
    Methods Mol Med; 2005; 106():3-10. PubMed ID: 15375309
    [No Abstract]   [Full Text] [Related]  

  • 53. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does antisense make sense in dermatology?
    van Erp PE; Wingens M
    Acta Derm Venereol; 2001; 81(6):385-91. PubMed ID: 11859937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oligonucleotide therapeutics for human leukaemia.
    Gewirtz AM
    Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ribosomal protein P2: a potential molecular target for antisense therapy of human malignancies.
    Gardner-Thorpe J; Ito H; Ashley SW; Whang EE
    Anticancer Res; 2003; 23(6C):4549-60. PubMed ID: 14981896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antisense oligonucleotides for central nervous system tumors.
    Hall WA; Flores EP; Low WC
    Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survivin as a target for new anticancer interventions.
    Zaffaroni N; Pennati M; Daidone MG
    J Cell Mol Med; 2005; 9(2):360-72. PubMed ID: 15963255
    [TBL] [Abstract]